Huub Schellekens
#130,253
Most Influential Person Now
Huub Schellekens's AcademicInfluence.com Rankings
Huub Schellekensbiology Degrees
Biology
#8542
World Rank
#11637
Historical Rank
Immunology
#493
World Rank
#510
Historical Rank

Download Badge
Biology
Huub Schellekens's Degrees
- PhD Immunology University of Amsterdam
- Masters Biology University of Amsterdam
Similar Degrees You Can Earn
Why Is Huub Schellekens Influential?
(Suggest an Edit or Addition)Huub Schellekens's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- γ Interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites (1987) (713)
- Structure-Immunogenicity Relationships of Therapeutic Proteins (2004) (547)
- Immunogenicity of therapeutic proteins: clinical implications and future prospects. (2002) (505)
- Bioequivalence and the immunogenicity of biopharmaceuticals (2002) (498)
- The hepatitis delta (δ) virus possesses a circular RNA (1986) (431)
- Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. (1986) (328)
- TRANSMISSION OF HEPATITIS B FROM HEPATITIS-B-SERONEGATIVE SUBJECTS (1988) (306)
- Factors influencing the immunogenicity of therapeutic proteins. (2005) (305)
- The Immunogenicity of Polyethylene Glycol: Facts and Fiction (2013) (299)
- Safety-related regulatory actions for biologicals approved in the United States and the European Union. (2008) (236)
- Immunogenicity of biopharmaceuticals. (2006) (226)
- Biosimilar therapeutics—what do we need to consider? (2009) (214)
- The purification and characterization of rat gamma interferon by use of two monoclonal antibodies. (1986) (203)
- Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis (2010) (200)
- γ‐interferon treatment inhibits collagen deposition in murine schistosomiasis (1989) (200)
- Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. (2006) (197)
- Immunological mechanism underlying the immune response to recombinant human protein therapeutics. (2010) (192)
- Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. (2014) (186)
- Cytokines and the immune response (1996) (159)
- Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses (1995) (157)
- The hepatitis delta (delta) virus possesses a circular RNA. (1986) (157)
- Immunogenicity of recombinant human proteins: causes and consequences (2004) (152)
- Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice (2012) (144)
- Immunogenicity of Therapeutic Proteins: The Use of Animal Models (2011) (141)
- Immunogenicity of therapeutic proteins. (2003) (140)
- Structural Characterization and Immunogenicity in Wild-Type and Immune Tolerant Mice of Degraded Recombinant Human Interferon Alpha2b (2005) (135)
- Follow-on biologics: challenges of the "next generation". (2005) (133)
- Cloning and expression of the chromosomal immune interferon gene of the rat. (1985) (133)
- Hepatitis B virus antigens made in microbial cells immunise against viral infection. (1984) (130)
- Taking immunogenicity assessment of therapeutic proteins to the next level. (2011) (130)
- Micelle-Associated Protein in Epoetin Formulations: A Risk Factor for Immunogenicity? (2003) (121)
- Monoclonal antibodies to human immune interferon and their use in a sensitive solid-phase ELISA. (1985) (119)
- Hybrid mass spectrometry approaches in glycoprotein analysis and their usage in scoring biosimilarity (2016) (113)
- Oxidized and Aggregated Recombinant Human Interferon Beta is Immunogenic in Human Interferon Beta Transgenic Mice (2011) (113)
- Immunogenicity of mAbs in non-human primates during nonclinical safety assessment (2013) (108)
- Quality of Original and Biosimilar Epoetin Products (2010) (105)
- Interchangeability, immunogenicity and biosimilars (2012) (105)
- Polyphosphate nanoparticles on the platelet surface trigger contact system activation. (2017) (105)
- Clinical comparability and European biosimilar regulations (2010) (103)
- Identification and transmission of hepatitis B virus-related variants. (1986) (102)
- The therapeutic equivalence of complex drugs. (2011) (101)
- The safety of switching between therapeutic proteins (2012) (100)
- Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. (2012) (99)
- How similar do 'biosimilars' need to be? (2004) (97)
- How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider (2013) (95)
- How to predict and prevent the immunogenicity of therapeutic proteins. (2008) (92)
- Immunologic mechanisms of EPO-associated pure red cell aplasia. (2005) (92)
- Iatrogenic meningitis by Streptococcus salivarius following lumbar puncture. (1995) (91)
- Aggregated Recombinant Human Interferon Beta Induces Antibodies but No Memory in Immune-Tolerant Transgenic Mice (2010) (89)
- Biosimilar Epoetins: An Analysis Based on Recently Implemented European Medicines Evaluation Agency Guidelines on Comparability of Biopharmaceutical Proteins (2005) (88)
- Pure red cell aplasia induced by erythropoiesis-stimulating agents. (2008) (87)
- Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis (2005) (86)
- Health risks of genetically modified foods (1999) (82)
- On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. (2010) (79)
- Immunological Risk of Injectable Drug Delivery Systems (2009) (78)
- The Cost‐Effectiveness of Drug Regulation: The Example of Thorough QT/QTc Studies (2012) (77)
- Influence of interferon preparations on the proliferative capacity of human and mouse bone marrow cells in vitro. (1978) (75)
- Eprex-associated pure red cell aplasia and leachates (2006) (75)
- Good laboratory practice for clinical next-generation sequencing informatics pipelines (2015) (74)
- When biotech proteins go off-patent. (2004) (72)
- Glomerular mesangial cells in local inflammation. Induction of the expression of MHC class II antigens by IFN-gamma. (1989) (72)
- Development of a Transgenic Mouse Model Immune Tolerant for Human Interferon Beta (2005) (70)
- Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene. (2012) (67)
- Antibodies against Erythropoietin and Other Protein‐Based Therapeutics: An Overview (2005) (65)
- Antiviral effect of interferon in vivo may be mediated by the host (1979) (63)
- The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development. (2003) (60)
- IMPACT OF CLASS II MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGEN EXPRESSION ON THE IMMUNOGENIC POTENTIAL OF ISOLATED RAT VASCULAR ENDOTHELIAL CELLS (1987) (60)
- 'Biogenerics': the off-patent biotech products. (2002) (60)
- Interferon Beta: From Molecular Level to Therapeutic Effects. (2016) (58)
- Immunogenicity of bone morphogenetic proteins. (2009) (57)
- Safety and efficacy of biosimilars in oncology. (2016) (56)
- The first biosimilar epoetin: but how similar is it? (2008) (56)
- Erythropoietin-Associated PRCA: Still an Unsolved Mystery (2006) (55)
- Conditional Approval and Approval Under Exceptional Circumstances as Regulatory Instruments for Stimulating Responsible Drug Innovation in Europe (2010) (51)
- Different Pharmaceutical Products Need Similar Terminology (2013) (51)
- Protective immunisation against hepatitis B with an internal antigen of the virus (1987) (50)
- Comparative antiviral efficiency of leukocyte and bacterially produced human α-interferon in rhesus monkeys (1981) (50)
- Immunogenicity of rDNA-derived pharmaceuticals. (2002) (49)
- The ability of animal studies to detect serious post marketing adverse events is limited. (2012) (49)
- Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies (2019) (48)
- Isolation and characterization of monoclonal antibodies directed to rat interferon-gamma. (1989) (47)
- Tumour necrosis factor α, interferon γ and interferon β exert antiviral activity in nervous tissue cells (1991) (47)
- Induction of Natural Killer Cell Activity and Allocytotoxicity in Human Peripheral Blood Lymphocytes after Mixed Lymphocyte Culture (1981) (47)
- Towards a sustainable system of drug development. (2014) (46)
- Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference (2005) (45)
- Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis (2004) (45)
- Assessing the bioequivalence of biosimilars The Retacrit case. (2009) (45)
- Neutralising antibodies to interferon β in multiple sclerosis (2007) (42)
- Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta. (2010) (42)
- Reduced synthesis of pp60src and expression of the transformation-related phenotype in interferon-treated Rous sarcoma virus-transformed rat cells (1983) (41)
- The immunogenicity of biopharmaceuticals (2003) (41)
- Cloning, expression, and purification of rat IFN-gamma. (1986) (40)
- Aggregation and Immunogenicity of Therapeutic Proteins (2010) (40)
- FIBROBLAST INTERFERON IN HBsAg-POSITIVE CHRONIC ACTIVE HEPATITIS (1977) (38)
- Making individualized drugs a reality (2017) (38)
- Production and initial characterization of rat interferon. (1980) (38)
- Suppression and augmentation of rat adjuvant arthritis with monoclonal anti-interferon-gamma antibody. (1989) (37)
- An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products. (2011) (36)
- Animal models in AIDS (1990) (36)
- The value of non-human primates in the development of monoclonal antibodies (2013) (34)
- Assays for antibodies to human interferon-alpha: the need for standardization. (1997) (33)
- Structure and expression in Escherichia coil of a cloned rat interferon-α gene (1984) (33)
- A standardised framework to identify optimal animal models for efficacy assessment in drug development (2018) (32)
- Plasmodium falciparum: studies on mature exoerythrocytic forms in the liver of the chimpanzee, Pan troglodytes. (1990) (31)
- Biosimilar therapeutic agents: issues with bioequivalence and immunogenicity (2004) (31)
- Longitudinal analysis of hepatitis C virus infection and genetic drift of the hypervariable region. (1994) (30)
- Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine). (1990) (30)
- Anti-cytokine autoantibodies: Epiphenomenon or critical modulators of cytokine action (1997) (30)
- Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. (2007) (30)
- Effect of treatment with interferon and cyclophosphamide on the growth of a spontaneous liposarcoma in rats (1983) (29)
- Hepatitis delta virus cDNA sequence from an acutely HBV‐infected chimpanzee: Sequence conservation in experimental animals (1991) (28)
- Are we ready to close the discussion on the interchangeability of biosimilars? (2019) (28)
- Are some animal models more equal than others? A case study on the translational value of animal models of efficacy for Alzheimer''s disease. (2019) (28)
- Double‐blind study of interferon administration in renal transplant recipients (1978) (27)
- The immunogenicity of therapeutic proteins. (2010) (27)
- Complete nucleotide sequence and viral envelope protein expression of a hepatitis B virus DNA derived from a hepatitis B surface antigen-seronegative patient. (1993) (26)
- Circulating interferon in rabbits and monkeys after administration of human gamma interferon by different routes. (1983) (26)
- How Bio-questionable are the Different Recombinant Human Erythropoietin Copy Products in Thailand? (2014) (26)
- Relationship between biopharmaceutical immunogenicity of epoetin alfa and pure red cell aplasia (2003) (25)
- Differential sensitivity of Rauscher murine leukaemia virus (MuLV-R) to interferons in two interferon-responsive cell lines. (1976) (25)
- The Pharmacokinetic and Biological Activity Profile of Dexamethasone Targeted to Sinusoidal Endothelial and Kupffer Cells (2003) (25)
- Effect of Treatment Regimen on the Immunogenicity of Human Interferon Beta in Immune Tolerant Mice (2013) (25)
- Influence of input multiplicity of infection on the antiviral activity of interferon. (1980) (24)
- Biosimilar monoclonal antibodies: the scientific basis for extrapolation (2015) (24)
- The Rebif® New Formulation Story (2007) (24)
- Influence of Aggregation and Route of Injection on the Biodistribution of Mouse Serum Albumin (2014) (24)
- Differential effects of fibroblast and leucocyte interferon in HBsAg positive chronic active hepatitis (1979) (22)
- Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab. (2013) (22)
- Effect of recombinant interferon gamma and interleukin-2 and of a monoclonal antibody against interferon gamma on the rat immune response against heart allografts. (1991) (21)
- Recombinant human erythropoietins, biosimilars and immunogenicity. (2008) (21)
- Contribution of animal studies to evaluate the similarity of biosimilars to reference products. (2015) (21)
- Antagonistic effects of gamma interferon and steroids on tissue antigenicity (1986) (21)
- Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products. (2016) (21)
- Effective pharmaceutical regulation needs alignment with doctors. (2012) (21)
- Prevention of vaccinia lesions in Rhesus monkeys by human leucocyte and fibroblast interferon. (1980) (20)
- Chapter 6 Structural characterization and immunogenicity in wildtype and immune tolerant mice of degraded recombinant human interferon alpha 2 b (2005) (20)
- Appropriate Conditions for Maintenance of Chimpanzees in Studies With Blood‐Borne Viruses: An Epidemiologic and Psychosocial Perspective (1989) (19)
- Immunogenicity of Recombinant Human Interferon Beta-1b in Immune-Tolerant Transgenic Mice Corresponds with the Biophysical Characteristics of Aggregates. (2016) (19)
- How institutional logics hamper innovation: The case of animal testing (2017) (18)
- The constrained prescription, interchangeability and substitution of biosimilars (2015) (18)
- Neonatal Host Defense Mechanisms against Listeria monocytogenes Infection: The Role of Lipopolysaccharides and Interferons (1989) (18)
- A novel oral iron-complex formulation: Encapsulation of hemin in polymeric micelles and its in vitro absorption. (2016) (18)
- Iron nanomedicines induce Toll-like receptor activation, cytokine production and complement activation. (2017) (17)
- Label-free glycoprofiling with multiplex surface plasmon resonance: a tool to quantify sialylation of erythropoietin. (2015) (17)
- Hemoglobin Variability in Patients with Chronic Kidney Disease in the Netherlands (2009) (17)
- Rat cytomegalovirus: induction of and sensitivity to interferon. (1983) (17)
- Thirty years of preclinical safety evaluation of biopharmaceuticals: did scientific progress lead to appropriate regulatory guidance? (2012) (17)
- Chemical inactivation of hepatitis B virus: the effect of disinfectants on virus-associated DNA polymerase activity, morphology and infectivity. (1983) (17)
- The immunogenicity of therapeutic proteins and the Fabry antibody standardization initiative. (2008) (16)
- Effect of Arginine on Pre-nucleus Stage of Interferon Beta-1b Aggregation (2014) (16)
- Antibody Response Against Betaferon® in Immune Tolerant Mice: Involvement of Marginal Zone B-cells and CD4+ T-cells and Apparent Lack of Immunological Memory (2012) (16)
- B-1 cells and naturally occurring antibodies: influencing the immunogenicity of recombinant human therapeutic proteins? (2009) (16)
- Development of a transgenic mouse model to study the immunogenicity of recombinant human insulin. (2014) (15)
- Treatment of Juvenile Laryngeal Papillomatosis with Two Types of Interferon (1982) (15)
- Mechanism of escape of exoerythrocytic forms (EEF) of malaria parasites from the inhibitory effects of interferon-gamma. (1987) (15)
- The effects of dodecyl maltoside and sodium dodecyl sulfate surfactants on the stability and aggregation of recombinant interferon Beta-1b. (2014) (15)
- Correction: A standardised framework to identify optimal animal models for efficacy assessment in drug development (2019) (15)
- The Cost‐Effectiveness of Periodic Safety Update Reports for Biologicals in Europe (2013) (14)
- Vascular endothelium in allograft rejection. (1988) (14)
- Human interferon does not protect cowpea plant cell protoplasts against infection with alfalfa mosaic virus. (1985) (14)
- Simple method for measuring growth inhibition by interferon of cells in monolayer. (1980) (14)
- Baculovirus-directed high level expression of the hepatitis delta antigen in Spodoptera frugiperda cells. (1991) (14)
- Oromucosal interferon therapy: relationship between antiviral activity and viral load. (2001) (14)
- Antiviral activity of interferon in rats and the effect of immune suppression. (1984) (14)
- Development of a bioassay for quantification of neutralising antibodies against human interferon-beta in mouse sera. (2008) (13)
- In vivo antiproliferative effects of gamma-interferon and tumor necrosis factor alpha in a rat renal cell carcinoma model system. (1990) (13)
- Treatment of Juvenile laryngeal papillomatosis with two types of interferon. (1982) (13)
- Reassessments of ESAs for cancer treatment in the US and Europe. (2010) (13)
- Isolation of parainfluenza virus type 3 from cerebrospinal fluid. (1992) (13)
- Reaction to the paper: Interaction of Polysorbate 80 with Erythropoietin: A Case Study in Protein–Surfactant Interactions (2006) (13)
- Chimpanzees and AIDS research (1988) (13)
- Detection of Chlamydia trachomatis in clinical specimens Comparison of culture, direct antigen detection, DNA probe hybridization and PCR (1994) (13)
- Recombinant interferon-γ applied to the brain ventricular system protects rats against pseudorabies (1990) (13)
- The Chimpanzee as a Model to Test the Side Effects of Human Interferons (1984) (13)
- Today’s Challenges in Pharmacovigilance (2011) (12)
- Serum capacity to inhibit reverse transcriptase in vitro distinguishes HIV-1 infection from HIV-2 or SIV infection. (1989) (12)
- Pharmacokinetic Studies with Human and Rat Interferons-γ in Different Species (1986) (12)
- The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals (2012) (12)
- The risk-based approach to ATMP development - generally accepted by regulators but infrequently used by companies. (2013) (12)
- Antiviral and side effects of interferons produced by recombinant DNA techniques as tested in rhesus monkeys. (1982) (12)
- Liposome‐targeted recombinant human acid sphingomyelinase: Production, formulation, and in vitro evaluation (2019) (12)
- Impact of Biosimilar Insulins on Clinical Practice (2014) (11)
- Natural antibodies against bone morphogenic proteins and interferons in healthy donors and in patients with infections linked to type-1 cytokine responses. (2011) (11)
- Hepatitis C virus antibody detection by a line ImmunoAssay and (near) full length genomic RNA detection by a new RNA‐capture polymerase chain reaction (1992) (11)
- The Biology of the Interferon System 1986 (1987) (11)
- The sponsored pandemic of the Mexican flu? (2011) (11)
- Tradition, not science, is the basis of animal model selection in translational and applied research. (2020) (10)
- Antiviral activity of human leucocyte interferon in rhesus monkeys and marmosets (1981) (10)
- Cloning, expression, and purification of rat IFN-alpha 1. (1986) (10)
- The protection of chimpanzees against hepatitis B viral infection using a recombinant yeast-derived hepatitis B surface antigen. (1987) (10)
- A sensitive two-site enzyme immunoassay for the detection of rat interferon-gamma in biological fluids. (1990) (10)
- Antiviral activity of recombinant rat interferon gamma in immunologically impaired and immunosuppressed rats. (1988) (10)
- Phytohaemagglutinin-induced susceptibility to lysis by natural and activated killer cells of autologous allogeneic and xenogeneic target cells. (1982) (10)
- A phase I clinical tolerance study of rDNA alpha 2 human interferon in patients with non-reticuloendothelial system malignancies. (1983) (9)
- Biosimilars or semi-similars? (2015) (9)
- Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product (2018) (9)
- In vivo immune stimulation by interferon during viral infection. (1981) (9)
- Differences Between Post-Authorization Adverse Drug Reactions of Biopharmaceuticals and Small Molecules (2013) (9)
- Drug regulatory systems must foster innovation. (2011) (9)
- Letter 2: Equivocal role of micelles in Eprex adverse events (2003) (9)
- Erythropoietic proteins and antibody-mediated pure red cell aplasia: a potential role for micelles. (2004) (9)
- Value for money of drug regulation (2012) (8)
- Erratum: Making individualized drugs a reality (2017) (8)
- Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have? (2006) (8)
- The influence of emetine on the induction of interferon by poly-I: poly-C in Swiss mice. (1975) (8)
- Tumour necrosis factor-alpha, interferon-gamma and interferon-beta exert antiviral activity in nervous tissue cells. (1991) (8)
- Prophylactic use of interferon in renal allograft recipients. (1979) (8)
- Development of ADA against recombinant human interferon beta in immune tolerant mice requires rapid recruitment of CD4⁺ T cells, induces formation of germinal centers but lacks susceptibility for (most) adjuvants. (2015) (8)
- A Cohort Study Exploring Determinants of Safety-Related Regulatory Actions for Biopharmaceuticals (2012) (8)
- Clinical and immunologic staging of feline immunodeficiency virus (FIV) infection. (1990) (7)
- Biological effect of interferon-gamma during the course of experimental infection of rat by Schistosoma mansoni. (1990) (7)
- Biosimilars need comparative clinical data. (2011) (7)
- Neonatal Listeria monocytogenes Infection is Refractory to Interferon (1991) (7)
- A modified immune tolerant mouse model to study the immunogenicity of recombinant human interferon beta. (2014) (7)
- Willingness to Pay for Adverse Drug Event Regulatory Actions (2011) (7)
- The effects of recombinant and natural human interferons in vaccinia virus infected rhesus monkeys. (1985) (7)
- Comparison of drug efficacy in two animal models of type 2 diabetes: A systematic review and meta-analysis. (2020) (6)
- Protection of Rats against Pseudorabies Virus Infection by γ-Interferon (1989) (6)
- Efficacy and toxicity of interferons in experimental animals. (1987) (6)
- The effect of recombinant human interferon α BD compared to interferon α 2b on SIV infection in rhesus macaques (1996) (6)
- Leukocyte binding and Ia-expression in vascular endothelium. (1987) (6)
- An Albumin-Free Formulation for Escherichia coli-Derived Interferon Beta-1b with Decreased Immunogenicity in Immune Tolerant Mice. (2016) (6)
- Biopharmaceutical molecules are not created equally (2002) (6)
- Immunogenicity of biopharmaceuticals. The European perspective. (2003) (5)
- Additive and synergistic antitumor effects with toremifene and interferons. (1990) (5)
- Lesson Learned from Eprex-Associated Pure Red Cell Aplasia (2007) (4)
- Growth inhibition and eicosanoid metabolism in the R3230AC mammary adenocarcinoma by interferon. (1986) (4)
- Relationship between the cellular expression of the antiviral and anticellular activities of interferon. (1981) (4)
- Pathways in the Drug Development for Alzheimer’s Disease (1906-2016): A Bibliometric Study (2020) (4)
- Biological and molecular characterization of the hepatitis delta virus. (1987) (4)
- Neutralizing antibodies to interferon beta in patients with multiple sclerosis: scientific background and clinical implications (2004) (4)
- The clinical value of interferon--a critical appraisal. (1981) (3)
- Reply to In support of the European Union biosimilar framework (2012) (3)
- Monkeys are insensitive to pyrogenic effects of human α-interferons (reply) (1982) (3)
- Immunogenicity of Antibody Therapeutics (2008) (3)
- Erratum: Making individualized drugs a reality (2017) (3)
- Structure and expression in Escherichia coli of a cloned rat interferon-alpha gene. (1984) (3)
- Immunogenicity of Therapeutic Proteins and the Assessment of Risk (2010) (3)
- The Cost-Effectiveness of Periodic Safety Update Reports (PSURS) for Biologicals in Europe (2013) (3)
- THE TOXICITY OF HUMAN INTERFERONS IN NONHUMAN PRIMATES (1982) (3)
- The biology of the interferon system 1985 : proceedings of the 1985 TNO-ISIR Meeting on the Interferon System, held in Clearwater Beach, Florida, USA on 13-18 October, 1985 (1986) (3)
- Production, purification, and characterization of rat interferon from transformed rat cells. (1986) (3)
- [Overregulation and unnecessary animal testing: requirements for market approval of biopharmaceuticals too rigid]. (2012) (2)
- Approved in the United States and the European Union Safety-Related Regulatory Actions for Biologicals (2008) (2)
- The biology of the interferon system 1984 : proceedings of the 1984 TNO-ISIR Meeting on the Interferon System, held in Heidelberg, Federal Republic of Germany on 21-25 October, 1984 (1985) (2)
- Protection of rats against pseudorabies virus infection by gamma-interferon. (1989) (2)
- Post-innovation innovation of medicinal products. (2011) (2)
- The contribution of periodic safety reports (PSURs) to safety related regulatory actions of biopharmaceuticals (2010) (2)
- Immunogenicity of therapeutique proteins: Clinical implication and futur prospects. Editorial comment (2002) (2)
- Prophylaxis and therapy of HBsAg positive hepatitis. (1979) (2)
- The effect of recombinant human interferon alpha B/D compared to interferon alpha 2b on SIV infection in rhesus macaques. (1996) (2)
- Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. (2007) (2)
- Between clones and clinic. (1988) (2)
- Differential effects of exogenous fibroblast and leucocyte interferon in HBsAg chronic hepatitis (1978) (2)
- Evaluation of the suitability of a Sprague Dawley rat model to assess intravenous iron preparations. (2018) (2)
- The biology of the interferon system : proceedings of the International Meeting on the Biology of the Interferon System held in Rotterdam, the Netherlands, on 21-24 April, 1981 (1981) (2)
- Efficacy and safety of orally/sublingually, intranasally, and intraperitoneally administered recombinant murine interferon in the treatment of murine encephalomyocarditis virus. (2001) (2)
- Animal models in AIDS: International TNO meeting, Maastricht, Netherlands, 23-26 October 1989. (1990) (1)
- Interferon Studies in Non-Human Primates (1988) (1)
- EFFECT OF MULTIPLICITY OF INFECTION ON THE ANTIVIRAL ACTION OF INTERFERON IN VITRO (1980) (1)
- Antitumor Effects of Rat Rec.Ifn-γ in Rats Bearing Transplantable Rat Tumors (1987) (1)
- Modulation of the immune response by interferon gamma administration in a rat cardiac allograft model. (1989) (1)
- Non Biologic Complex Drug Concept: Experiences with Iron Sucrose and LowMolecular Weight Heparin (2014) (1)
- Feasibility Study for Bedside Production of Recombinant Human Acid α-Glucosidase: Technical and Financial Considerations. (2020) (1)
- Cytokine Yearbook Volume 1 (1996) (1)
- Pharmacokinetic studies with human and rat interferons-gamma in different species. (1986) (1)
- Erythropoiesis-stimulating Agents – Present and Future (2006) (1)
- Animal models in interferon research: Some current trends (1989) (1)
- AIDS: Questions and answers: by V.G. Daniels Cambridge Medical Books, Cambridge, 1986 95 pages (1986) (1)
- Biomarkers for the Immunogenicity of Therapeutic Proteins and Its Clinical Consequences (2010) (1)
- Role of interferon-γ on the in vivo expression of functional interleukin-2 receptors by murine macrophages (1991) (1)
- Concomitant enhancement of a cytoskeleton-associated 76,000-dalton protein and inhibition of fluid-phase pinocytosis by interferon-alpha in Fujinami sarcoma virus-transformed rat 3Y1 cells. (1986) (0)
- Effective antiviral prophylaxis with human interferons in a rhesus monkey model. (1981) (0)
- Implementation of in vitro replacement technologies in regulatory drug testing - An innovation systems perspective (2011) (0)
- The future of non-human primates in the development of biopharmaceuticals (2012) (0)
- Differences Between Post-Authorization Adverse Drug Reactions of Biopharmaceuticals and Small Molecules (2013) (0)
- The quality of post marketing surveillance of biotech drugs (2008) (0)
- Antibody Assays in Animal Research (2011) (0)
- Different Pharmaceutical Products Need Similar Terminology (2013) (0)
- High dose interferon alpha B/D in patients with chronic hepatitis B. (1996) (0)
- Immune mechanisms underlying immunogenicity of aggregated recombinant human interferon alpha‐2a in immune tolerant mice (2013) (0)
- Opening Keynote and Introductory Session (2010) (0)
- Interferon as an Antiviral Agent (1988) (0)
- The biology of the interferon system 1983 : proceedings of the Second International TNO Meeting on the Biology of the Interferon System, held in Rotterdam, The Netherlands, on 18-22 April, 1983 (1983) (0)
- The value of non-human primates in the development of therapeutic monoclonal antibodies (2011) (0)
- Interferons, properties and applications (1980) (0)
- [Virus infections in kidney transplant patients]. (1977) (0)
- The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals (2012) (0)
- Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (2007) (0)
- Transition towards replacing animal tests in safety assessment of cosmetics and chemicals: a combined TIS-MLP framework (2012) (0)
- The outcome of psur assessments of biopharmaceuticals (2011) (0)
- Review of: "Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution" (2022) (0)
- Antibodies in Cytokines (1997) (0)
- Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product (2018) (0)
- Evolution of the immune system and invertebrate immunity (PP-009) (2010) (0)
- Factors inhibiting IFN activity (1996) (0)
- The challenge of regulating biologicals: the PRCA controversy and the creation of the European biosimilar regulatory framework (2013) (0)
- Rigaud and Schmincke Types of Lymphoepithelioma (2011) (0)
- Infectious hepatitis B virus from cl nucleotide sequence (chimpanzee transfection/recombinant hepatitis B virus DNA/risk a: (2016) (0)
- Effect of Arginine on Pre-nucleus Stage of Interferon Beta-1b Aggregation (2014) (0)
- A comparison of post-authorization adverse events of biopharmaceuticals and small molecules within the same anatomical therapeutic chemical class (2012) (0)
- Antibodies in Cytokines: The concerted action on the antigenicity of rDNA derived pharmaceuticals (1997) (0)
- Reply to: Equivocal role of micelles in Eprex adverse events (2003) (0)
- Whatever happened to acid rain (2004) (0)
- Safety Warnings Issued for Biotechnology Derived Pharmaceuticals Approved Since 1995 (2007) (0)
- The Antigenicity of Recombinant‐DNA‐derived Pharmaceuticals (1997) (0)
- How Bio-questionable are the Different Recombinant Human Erythropoietin Copy Products in Thailand? (2013) (0)
- Realising the Full Potential of Biosimilars: Interviews with Three Key Opinion Leaders (2018) (0)
- Understanding transition dynamics using a combined TIS-MLP approach (2012) (0)
- [Interferon and virus infections]. (1977) (0)
- Interferons: past, present and future (1985) (0)
- A future for exogenous interferon therapy? (1978) (0)
- Efficacy of a novel interferon alpha B/D, given in high dose. Monitored by quantitative HBeAg, HBsAg and HBV-DNA in patients with chronic hepatitis B. (1996) (0)
- Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs (2023) (0)
- Poster Presentations (2007) (0)
- Spending on BSE research (1996) (0)
- The cost-effectiveness of drug regulation (2008) (0)
- Protein quality testing in the era of personalized medicine. (2020) (0)
- How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider (2013) (0)
- The transition to a sustainable system of drug development requires reformation of the regulatory and patent systems, and a shift of responsibility to open-access discovery and clinical evaluation of innovative drugs to the public sector. (2014) (0)
- A divided INN crowd (2014) (0)
- The risk-based approach to ATMP development – Generally accepted by regulators but infrequently used by companies Regulatory Toxicology and Pharmacology (2013) (0)
- Tolerance and Antiviral Effects of High-Dose Interferon-α B/D in Patients with Chronic Hepatitis B (1998) (0)
- The development and validation of immune tolerant mouse models to measure and predict the immunogenicity of monoclonal antibody (MAb) therapeutics (2007) (0)
- The Immunogenicity of Polyethylene Glycol: Facts and Fiction (2013) (0)
- Development of Rebif (R) New Formulation for MS treatment: consolidated results from preclinical and phase I studies (2007) (0)
- Understanding the lengthy process to replace the draize test (2012) (0)
- The Biology of the interferon system 1986 : proceedings of the 1986 ISIR-TNO meeting on the interferon system, 7-12 September 1986, Dipoli Congress Center, Espoo, Finland (1987) (0)
- Is it true what they say about interferon? (1979) (0)
- Safety and efficacy of biosimilar epoetins. (2004) (0)
- Effect of Treatment Regimen on the Immunogenicity of Human Interferon Beta in Immune Tolerant Mice (2013) (0)
- Antibody Response Against Betaferon® in Immune Tolerant Mice: Involvement of Marginal Zone B-cells and CD4+ T-cells and Apparent Lack of Immunological Memory (2012) (0)
- Responsible early diagnostics for Alzheimer's disease (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Huub Schellekens?
Huub Schellekens is affiliated with the following schools: